natgillin/translations-raw huggingface dataset:
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine andnicotine that use the same renal cationic transport system as amantadine may also possiblyi nteract with memantine leading to a potential risk of increased plasma levels.
Ostale zdravilne učinkovine, kot cimetidin, ranitidin, prokainamid, kinidin, kinin in nikotin, ki uporabljajo isti ledvični kationski transportni sistem kot amantadin, prav tako lahko interagirajo z memantinom, kar vodi v možnost zvišane plazemske vrednosti.
Other active substances: Dopamine receptor antagonists (e.g. some antipsychotics and antiemetics), phenytoin and papaverine may reduce the therapeutic effect of levodopa.
Druge zdravilne učinkovine: Antagonisti dopaminskih receptorjev (npr. nekateri antipsihotiki in antiemetiki), fenitoin in papaverin lahko zmanjšajo terapevtski učinek levodope.
Other adverse events observed in clinical studies were of a similar incidence in Trazec-treated and placebo-treated patients.
Drugi neželeni učinki, ki so bili opaženi v kliničnih študijah, so se pojavljali podobno pogosto pri bolnikih, ki so dobivali bodisi Trazec bodisi placebo.
Other adverse reactions have been identified during post approval use of NutropinAq.
Med uporabo zdravila NutropinAq v obdobju trženja so bili odkriti še nekateri drugi neželeni učinki.
Other adverse reactions observed in patients treated with ZYPADHERA were similar to those seen with oral olanzapine.
Drugi neželeni učinki, ki so jih opazovali pri bolnikih, zdravljenih z zdravilom ZYPADHERA so bili podobni tistim, ki so jih opazili pri peroralnem olanzapinu.
Other adverse reactions previously reported with one of the individual components may occur with Rasitrio even if not observed in clinical trials.
Pri uporabi zdravila Rasitrio lahko pride do drugih neželenih učinkov, o katerih so poročali pri ločeni uporabi posameznih učinkovin zdravila, čeprav teh neželenih učinkov niso opažali v kliničnih študijah.
Other adverse reactions previously reported with one of the individual components may occur with Riprazo HCT even if not observed in clinical trials.
Pri uporabi zdravila Riprazo HCT lahko pride do drugih neželenih učinkov, ki so jih prej opisali pri uporabi katere od posameznih sestavin, tudi če jih v kliničnih preskušanjih niso opažali.
Other adverse reactions previously reported with one of the individual components may occur with Sprimeo HCT even if not observed in clinical trials.
Pri uporabi zdravila Sprimeo HCT lahko pride do drugih neželenih učinkov, ki so jih prej opisali pri uporabi katere od posameznih sestavin, tudi če jih v kliničnih preskušanjih niso opažali.
Other adverse reactions:
Drugi neželeni učinki
OTHER AGENTS
DRUGA ZDRAVILA
Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5,
Drugi aleli, povezani z odsotno ali zmanjšano presnovo, so redkejši in vključujejo CYP2C19*4, *5, *6, *7 in *8.
Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5,
Drugi aleli, povezanimi z odstotno ali zmanjšano presnovo, so redkejši in vključujejo CYP2C19*4, *5, *6, *7 in
other allergic reactions tiredness
druge alergijske reakcije utrujenost
Other anti-cancer medicines as they may contribute to the release of too much uric acid when tumour cells are destroyed by asparaginase.
Druga zdravila z delovanjem na novotvorbe, ker lahko prispevajo k sproščanju prevelikih količin sečne kisline, ko asparaginaza uniči rakaste celice.
other anti-depressants (such as venlafaxine and tryptophan) used in major depression tricyclic’s (such as clomipramine and amitriptyline) used for depressive illness
druga antidepresivna zdravila (kot sta venlafaksin in triptofan) uporabljamo za močno depresijo,
Other anti-epileptic medicines, such as carbamazepine, oxcarbazepine, and phenytoin that are used to treat fits may affect Fycompa.
Druga antiepileptična zdravila, kot so karbamazepin, okskarbazepin in fenitoin, ki se uporabljajo za zdravljenje krčev, lahko vplivajo na zdravilo Fycompa.
Other Anti-infectives
Druga protiinfekcijska zdravila
other antidiabetics - either insulin or a sulphonylurea (such as glimepiride or glipizide) – your doctor may want to reduce your dose in order to avoid your blood sugar level from getting too low (hypoglycaemia) medicines used to lower your blood pressure (anti-hypertensives), including diuretics (medicines used to remove levels of excess water in the body, also known as water tablets) since this medicine can also lower your blood pressure by removing levels of excess water in the body.
druga zdravila za zniževanje koncentracije glukoze v krvi - bodisi insulin ali sulfonilsečnino (kot sta glimepirid ali glipizid) – zdravnik vam bo morda zmanjšal odmerek teh zdravil, da se vam koncentracija sladkorja v krvi ne bi preveč znižala (da ne bi prišlo do hipoglikemije) zdravila za zniževanje krvnega tlaka (antihipertenzivi), vključno z diuretiki (zdravila za izločanje prevelike količine vode iz telesa), ker tudi to zdravilo lahko zniža vaš krvni tlak tako, da poveča izločanje vode iz telesa.
Other antihypertensive agents: The antihypertensive effect of Rasilez HCT may be increased with the concomitant use of other antihypertensive agents.
Druga antihipertenzivna zdravila: Sočasna uporaba drugih antihipertenzivnih zdravil lahko okrepi antihipertenzivno delovanje zdravila Rasilez HCT.
Other antiretroviral agents: no specific recommendation can be made with regard to other available antiretroviral agents due to the lack of data.
Druga antiretrovirusna zdravila: zaradi pomanjkanja podatkov ni specifičnih priporočil glede drugih antiretrovirusnih zdravil, ki so na voljo.
Other antiretroviral medicinal products
Druga protiretrovirusna zdravila
Other Antiviral agents
Druga protivirusna zdravila
Other associated risk factors should be considered to avoid lactic acidosis such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic impairment and any condition associated with hypoxia (such as decompensated cardiac failure, acute myocardial infarction) (see section 4.3).
Da bi preprečili pojav laktacidoze je treba upoštevati tudi druge povezane dejavnike tveganja, kot so slabo nadzorovana sladkorna bolezen, ketoza, dolgotrajnejši post, čezmerno uživanje alkohola, jetrna okvara in vsako stanje, ki je povezano s hipoksijo (kot je dekompenzirano srčno popuščanje, akutni miokardni infarkt) (glejte poglavje 4.3).
Other associations include rash, bronchospasm, lymphadenopathy, haemolytic anaemia, vasculitis, uveitis, angioedema, agranulocytosis, the sicca syndrome, myalgia, elevation in serum levels of skeletal-muscle enzymes, and pneumonitis.
Druge povezave vključujejo izpuščaj, bronhospazem, limfadenopatijo, hemolitično anemijo, vaskulitis, uveitis, angioedem, agranulocitozo, Sjögrenov sindrom, mialgijo, povišanje ravni skeletnomišičnih encimov v serumu in pnevmonitis.
Other autoimmune conditions
Druge avtoimunske bolezni
Other binding proteins may be elevated in serum, i.e. corticoid binding globulin (CBG), sex-hormone-binding globulin (SHBG) leading to increased circulating corticosteroids and sex steroids, respectively.
Koncentraciji drugih vezavnih beljakovin, t.j. globulina, ki veže kortikoide (CBG – corticoid binding globulin) in globulina, ki veže spolne hormone (SHBG – sex-hormone-binding globulin), se lahko v serumu zvečata, kar zviša raven kortikosteroidov in spolnih steroidov v krvnem obtoku.
Other bleeding (including epistaxis, post-procedural haemorrhage and haematuria)
druga krvavitev (vključno z epistakso, s krvavitvijo po posegu in s hematurijo)
Other bleeding events (including events such as epistaxis, post-procedural haemorrhage and haematuria) were reported in 13.3% of patients treated with Jakavi and 10.3% treated with reference treatments.
O drugih krvavitvah (ki vključujejo dogodke, kot so epistaksa, krvavitev po posegu in hematurija) so poročali pri 13,3 % bolnikov, ki so prejemali zdravilo Jakavi, in pri 10,3 % tistih, ki so prejemali primerjalna zdravila.
Other bleeding events (including events such as epistaxis, post-procedural haemorrhage, gingival bleeding) were reported in 11.8% of patients treated with Jakavi and 6.3% treated with best available therapy.
O drugih krvavitvah (vključno z dogodki, kot so epistaksa, krvavitev po posegu ali krvavitev dlesni) so poročali pri 11,8 % bolnikov, ki so prejemali zdravilo Jakavi, in pri 6,3 % tistih, ki so prejemali najboljše razpoložljivo zdravljenje.
Other blood glucose lowering drugs excl. insulins.
Drugi antidiabetiki razen insulina.
other blood vessels
Krvni strdki, ki zamašijo druge žile
Other bronchodilators (such as salbutamol).
druge bronhodilatatorje (npr. salbutamol).
Other bronchodilators (such as salbutamol).
Drugi bronhodilatatorji (kot je salbutamol).
Other Candida spp.2
Druge vrste Candida spp.2
Other cases in which ChondroCelect cannot be supplied
Primeri, v katerih zdravila ChondroCelect ni mogoče uporabiti
Other causes of apnoea (e.g., central nervous system disorders, primary lung disease, anaemia, sepsis, metabolic disturbances, cardiovascular abnormalities, or obstructive apnoea) should be ruled out or properly treated prior to initiation of treatment with caffeine citrate.
Pred začetkom zdravljenja s kofeinijevim citratom je treba izključiti ali ustrezno zdraviti druge vzroke za apnejo (npr. bolezen osrednjega živčnega sistema, primarna bolezen pljuč, anemija, sepsa, motnje presnove, kardiovaskularne abnormalnosti ali obstruktivna apneja).
Other causes of frequent urination (heart failure or renal disease) should be assessed before treatment with Kentera.
Pred začetkom zdravljenja z zdravilom Kentera je treba oceniti druge vzroke za pogosto uriniranje (zdravljenje srčnega popuščanja ali ledvične bolezni).
other central nervous system depressants, other opioid derivatives (e.g. methadone, analgesics and antitussives), certain antidepressants, sedative H1-receptor antagonists, barbiturates, anxiolytics other than benzodiazepines, neuroleptics, clonidine and related substances: these combinations increase central nervous system depression.
Drugimi depresivi osrednjega živčnega sistema, drugimi opioidnimi derivativi (npr. metadon, analgetiki in antitusiki), nekaterimi antidepresivi, sedativnimi agonisti receptorja H1, barbiturati, anksiolitiki, ki niso benzodiazepini, nevroleptiki, klonidin in z njim povezanimi snovmi, saj te kombinacije povečajo depresijo osrednjega živčnega sistema.
Other changes in blood biochemical and haematological parameters probably associated with the use of prednisolone were significant effects noticed on lactate dehydrogenase (decrease) and abumin (increase) and on eosinophils, lymphocytes (decrease) and segmented neutrophils (increase).
Druge opažene spremembe biokemičnih in hematoloških parametrov krvi, ki so bile verjetno povezane z uporabo prednizolona, so bili pomembni učinki na laktat dehidrogenazo (znižanje) in albumin (zvišanje) ter eozinofilce, limfocite (znižanje) in segmentirane nevtrofilce (zvišanje).
Other changes in blood biochemical and haematological parameters probably associated with the use of prednisolone were significant effects noticed on lactate dehydrogenase (decrease) and albumin (increase) and on eosinophils, lymphocytes (decrease) and segmented neutrophils (increase).
Druge opažene spremembe biokemičnih in hematoloških parametrov krvi, ki so bile verjetno povezane z uporabo prednizolona, so bili pomembni učinki na laktat dehidrogenazo (znižanje) in albumin (zvišanje) ter eozinofilce, limfocite (znižanje) in segmentirane nevtrofilce (zvišanje).
Other clinically
Drugi klinično
Other clinically relevant severe side effectswere diabetes (common) and inflammation of the pancreas (uncommon).
Druga klinično pomembna resna neželena učinki sta bila sladkorna bolezen (pogosto)in vnetje trebušne slinavke (občasno).
Other CNS effects
Drugi učinki na osrednji živčni sistem
Other CNS effects including aggressive behaviour (sometimes directed against others such as homicidal ideation), bipolar disorder, mania,), confusion and alterations of mental status have been observed with alpha interferons.
Opažali so tudi druge učinke interferonov alfa na CŽS, vključno z agresivnostjo (ki je včasih usmerjena proti drugim, kot je ideja o umoru), bipolarna motnja, manija, zmedenostjo in spremembami duševnega statusa.
Other CNS effects including aggressive behaviour (sometimes directed against others such as homicidal ideation), bipolar disorders, mania, confusion and alterations of mental status have been observed with alfa interferons.
Pri zdravljenju z interferoni alfa so opazili tudi druge neželene učinke centralnega živčnega sistema, vključno z agresivnim vedenjem (včasih proti drugim osebam, npr. razmišljanje o umoru), bipolarnimi motnjami razpoloženja, manijo, zmedenostjo in spremembami duševnega stanja.
OTHER CODDITIONS AND REQUIREMENT OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER COMDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
Other common ( 1%) side effects are redness, feeling of warmth, pain, increased skin sensitivity (especially to hot and cold), skin tingling, rash, folliculitis (inflamed or infected hair follicles) and herpes viral infections (e.g. cold sores, generalised herpes simplex infections).
Drugi pogosti ( 1%) neželeni učinki so pordelost, občutek toplote, bolečina, zvečana občutljivost kože (zlasti za vročino in mraz), mravljinčenje na koži, izpuščaj, folikulitis (vnetje ali okužbe mešičkov dlak) in herpesvirusne okužbe (npr. ocvirki, razširjene okužbe s herpes simplex).
Other common eye side effects reported to be possibly caused by the medicine or by the injection procedure include:
Med drugimi pogostimi očesnimi neželenimi učinki, za katere je opisano, da so morda posledica zdravila ali postopka injiciranja, so:
Other common non-visual side effects reported to be possibly caused by the medicine or by the injection procedure include:
Druga pogosta neočesna neželena učinka, za katera je opisano, da sta morda posledica zdravila ali postopka injiciranja, sta:
Other common side effects
Drugi pogosti neželeni učinki
Other common side effects
Ostali pogosti neželeni učinki:
Other common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and in early treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males.
Drugi pogosti neželeni učinki (lahko se pojavijo pri največ 1 od 10 bolnikov) vključujejo spremembe v ravneh nekaterih krvnih celic in maščob v krvnem obtoku in v začetnih obdobjih zdravljenja, začasno zvišanje jetrnih encimov, zvišanja v ravni sladkorjev v krvi in urinu, zvišanja v ravni sečne kisline in kreatin-fosfokinaze v krvi, večji občutek lakote, omotico, nemirnost, tresenje, nenavadne gibe (diskinezijo), zaprtje, suha usta, izpuščaj, izgubo moči, hudo utrujenost, zadrževanje vode, ki vodi v otekanje rok, gležnjev ali nog, vročino, bolečine v sklepih ter spolne disfunkcije, kot na primer zmanjšan libido pri moških in ženskah ter erektilna disfunkcija pri moških.
Other common side effects (seen in more than 1 in 10 patients) that have been observed with hydrochlorothiazide alone are hypokalaemia (low blood potassium levels) and increases in blood cholesterol and triglyceride (a type of fat) levels.
Drugi najpogostejši neželeni učinki (opaženi pri 1 bolniku od 10) pri uporabi samo hidroklorotiazida so hipokaliemija (nizka raven kalija v krvi) in povišanje ravni holesterola ter triglicerida (vrste maščobe) v krvi.
Other common side effects are fever, anorexia (loss of appetite), vomiting, diarrhoea, irritability, somnolence (sleepiness), crying (including unusual high- pitched crying and prolonged crying) and otitis media (infection of the middle ear).
Drugi pogosti neželeni učinki so povišana telesna temperatura, anoreksija (izguba teka), bruhanje, driska, razdražljivost, zaspanost, jok (vključno z jokom z nenavadno visokim glasom in dolgotrajnim jokom) in otitis media (vnetje srednjega ušesa).
Other common side effects include lethargy (sluggishness), decreased appetite, diarrhoea, pruritus (itching), dermatitis (inflammation of the skin) and reddening of the skin and ear.
Med druge pogoste neželene učinke spadajo letargija (lenobnost), zmanjšanje teka, driska, pruritus (srbenje), dermatitis (vnetje kože) ter pordelost kože in uhljev.
Other common side effects of Keytruda related to the activity of the immune system causing inflammation of body organs.
Drugi pogosti neželeni učinki zdravila Keytruda so povezani z delovanjem imunskega sistema, ki povzroča vnetje organov.
Other common side effects that may affect up to 1 in 10 people are:
Drugi pogosti neželeni učinki, ki lahko prizadenejo največ 1 od 10 bolnikov, so:
Other common side effects(may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males.
Drugi pogosti neželeni učinki (lahko prizadenejo do 1 od 10 bolnikov) vključujejo spremembe v ravneh nekaterih krvnih celic, maščob v krvnem obtoku in v začetnih obdobjih zdravljenja, začasno povišanje jetrnih encimov, zvišanja v ravni sladkorjev v krvi in urinu, zvišanja v ravni sečne kisline in kreatin-fosfokinaze v krvi, večji občutek lakote, omotico, nemirnost, tresenje, nenavadne gibe (diskinezijo), zaprtje, suha usta, izpuščaj, izgubo moči, hudo utrujenost, zadrževanje vode, ki vodi v otekanje rok, gležnjev ali nog, vročino, bolečine v sklepih ter spolne disfunkcije, kot na primer zmanjšan libido pri moških in ženskah ter erektilna disfunkcija pri moških.
Other common side effects:
Drugi pogosti neželeni učinki:
Other common symptoms are: nausea (feeling sick), vomiting (being sick), diarrhoea, abdominal (stomach) pain, severe tiredness
Drugi pogosti simptomi so: slabost v želodcu (siljenje na bruhanje), bruhanje, driska, bolečine v trebuhu, huda utrujenost.
Other common symptoms are: nausea (feeling sick), vomiting (being sick), diarrhoea, abdominal (stomach) pain, severe tiredness
Drugi pogosti simptomi so: slabost, bruhanje, driska, bolečine v trebuhu, huda utrujenost.
Other common symptoms are: nausea (feeling sick), vomiting (being sick), diarrhoea, abdominal (stomach) pain, severe tiredness.
Drugi pogosti simptomi so: slabost, bruhanje, driska, bolečine v trebuhu, huda utrujenost.
Other commonly observed adverse reactions were in most cases mild or moderate:
Drugi pogosto opaženi neželeni učinki so bili v večini primerov blagi ali zmerni:
Other commonly occurring adverse drug reactions reported were dry mouth (8.6%), constipation (3.9%), diarrhoea (3.2%), headache (3.0%), dizziness (2.3%) and blurred vision (2.3%).
Druge pogoste neželene reakcije, o katerih so poročali, so bile suha usta (8,6 %), zaprtje (3,9 %), driska (3,2 %), glavobol (3,0 %), omotičnost (2,3 %) in zamegljen vid (2,3 %).
Other concomitant therapy
Drugo sočasno zdravljenje
Other conditions
Druga bolezenska stanja
OTHER CONDITIONS AND REQUIREMENT OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
C DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI ALI ZAHTEVE DOVOLJENJA ZA PROMET
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI ALI ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVA DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROM ET Z ZDRAVI LOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET S CEPIVOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM‌
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZAPROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE GLEDE DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE KI JIH MORA IZPOLNITI IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM>
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE V ZVEZI Z DOVOLJENJEM ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE, KI JIH MORA IZPOLNITI IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM>
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE, KI JIH MORA IZPOLONITI IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
POGOJI IN OMEJITVE V ZVEZI Z VARNO IN
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
POGOJI IN OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDARVILA
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
POGOJI IN OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
POSEBNE ZAHTEVE, KI JIH MORA IZPOLNITI IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
RUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
VÝROBCA (VÝROBCOVIA) ZODPOVEDNÝ (ZODPOVEDNÍ) ZA UVOĽNENIE ŠARŽE
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Za shranjevanje zdravila ni posebnih temperaturnih omejitev.
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION HOLDER
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION>
<D. DRUGI POGOJI IN ZAHTEVE KI JIH MORA IZPOLNITI IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM>
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION‌
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET S CEPIVOM‌
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION‌
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM